SK hynix Inc. (KRX:000660)

CTI BioPharma Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	77,211,245	66,192,960	32,765,719	44,621,568	42,997,792	31,900,418
Revenue Growth (YoY)	56.85%	102.02%	-26.57%	3.78%	34.79%	18.19%
Cost of Revenue	35,589,217	34,364,814	33,299,167	28,993,713	24,045,600	21,089,789
Gross Profit	41,622,028	31,828,146	-533,448	15,627,855	18,952,192	10,810,629
Selling, General & Admin	5,432,188	3,263,884	2,773,412	3,562,451	2,157,553	1,721,197
Research & Development	3,838,705	4,436,341	3,750,707	4,474,553	3,551,197	3,111,298
Other Operating Expenses	84,175	100,974	85,672	102,035	88,248	-
Operating Expenses	9,855,770	8,360,827	7,196,865	8,818,438	6,541,852	5,798,005
Operating Income	31,766,258	23,467,319	-7,730,313	6,809,417	12,410,340	5,012,624
Interest Expense	-970,005	-1,345,239	-1,468,273	-533,114	-259,960	-253,468
Interest & Investment Income	310,694	374,127	229,821	91,986	32,582	29,197
Earnings From Equity Investments	-69,297	-38,245	15,061	131,186	162,280	-36,279
Currency Exchange Gain (Loss)	151,684	268,826	-318,833	-405,228	488,617	-190,409
Other Non Operating Income (Expenses)	-41,951	-246,040	-2,551,693	-20,491	569,965	-60,728
EBT Excluding Unusual Items	31,147,383	22,480,748	-11,824,230	6,073,756	13,403,824	4,500,937
Gain (Loss) on Sale of Investments	1,900,251	-	-	-623,923	-3,402	1,763,855
Gain (Loss) on Sale of Assets	1,434,180	1,404,849	175,425	162,641	59,357	-11,211
Asset Writedown	3	-247	-9,011	-1,609,694	-43,792	-16,544
Pretax Income	34,481,817	23,885,350	-11,657,816	4,002,780	13,415,987	6,237,037
Income Tax Expense	5,617,762	4,088,448	-2,520,269	1,761,111	3,799,799	1,478,123
Earnings From Continuing Operations	28,864,055	19,796,902	-9,137,547	2,241,669	9,616,188	4,758,914
Minority Interest in Earnings	-11,823	-8,221	25,119	-12,109	-13,872	-3,812
Net Income	28,852,232	19,788,681	-9,112,428	2,229,560	9,602,316	4,755,102
Net Income to Common	28,852,232	19,788,681	-9,112,428	2,229,560	9,602,316	4,755,102
Net Income Growth	1054.69%	-	-	-76.78%	101.94%	137.05%
Shares Outstanding (Basic)	690	689	688	688	686	684
Shares Outstanding (Diluted)	690	710	688	688	687	684
Shares Change (YoY)	-1.27%	3.17%	0.04%	0.17%	0.37%	0.01%
EPS (Basic)	41850.62	28732.11	-13243.82	3242.31	13989.16	6951.89
EPS (Diluted)	39866.67	28418.66	-13244.00	3242.00	13984.00	6950.00
EPS Growth	998.17%	-	-	-76.82%	101.21%	137.04%
Free Cash Flow	15,616,419	13,850,351	-4,046,947	-4,229,744	7,311,013	2,245,909
Free Cash Flow Per Share	22632.49	19512.08	-5881.75	-6149.66	10647.19	3282.82
Dividend Per Share	1904.000	2204.000	1200.000	1200.000	1540.000	1170.000
Dividend Growth	5.78%	83.67%	-	-22.08%	31.62%	17.00%
Gross Margin	-	48.08%	-1.63%	35.02%	44.08%	33.89%
Operating Margin	41.14%	35.45%	-23.59%	15.26%	28.86%	15.71%
Profit Margin	37.37%	29.89%	-27.81%	5.00%	22.33%	14.91%
Free Cash Flow Margin	20.23%	20.92%	-12.35%	-9.48%	17.00%	7.04%
EBITDA	44,177,234	35,404,634	5,300,545	20,325,873	22,373,319	13,912,265
EBITDA Margin	-	53.49%	16.18%	45.55%	52.03%	43.61%
D&A For EBITDA	12,349,315	11,937,315	13,030,858	13,516,456	9,962,979	8,899,641
EBIT	31,766,258	23,467,319	-7,730,313	6,809,417	12,410,340	5,012,624
EBIT Margin	-	35.45%	-23.59%	15.26%	28.86%	15.71%
Effective Tax Rate	-	17.12%	-	44.00%	28.32%	23.70%
Advertising Expenses	-	123,462	83,575	113,401	93,050	95,158

Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.